Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SLDB with free AI briefings, catalyst countdowns, and dilution alerts.

SLDB · Solid Biosciences Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$348.9M Cash on Hand
21.3mo Cash Runway
13.5% Short Interest
$18.71 Analyst Target (14)
Follow SLDB by email Get an email when SLDB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SLDB, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SGT-003 Duchenne Muscular Dystrophy Phase 3 · NCT07160634 Recruiting
SGT-212 Friedreich's Ataxia (FA) Phase 1 · NCT07180355 Recruiting
SGT-501 Catecholaminergic Polymorphic Ventricular Tachycardia Phase 1 · NCT07148089 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SLDB holds $348.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $49.1M/quarter from operations, an estimated runway of 21.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 42 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SLDB files for a raise →

👥 Who Owns SLDB

Insiders 11.7% Other 5%+ holders 16.7% Institutions (215 holders) 71.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
Perceptive Advisors LLC Institution (13G, 5%+) 12,046,579 10.79% 2026-06-30
RA CAPITAL MANAGEMENT, L.P.
10% owner
Insider 12,036,126 10.78% 2026-11-04
Raymond Debbane 5%+ holder (13G) 10,066,682 9.02% 2026-03-31
Bain Capital Life Sciences Investors, LL Institution (13F) 9,808,819 8.79% 2026-09-30
BCLS II Investco, LP 5%+ holder (13D) 8,604,852 7.71% 2026-03-06
Siren, L.L.C. Institution (13F) 7,690,405 6.89% 2026-09-30
FMR LLC Institution (13G, 5%+) 6,875,957 6.16% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 6,419,730 5.75% 2026-06-30
RTW Investments LP Institution (13F) 5,905,426 5.29% 2026-09-30
Armistice Capital, LLC Institution (13F) 4,496,000 4.03% 2026-09-30
Franklin Resources, Inc. Institution (13F) 4,193,497 3.76% 2026-09-30
Franklin Templeton, Inc. Institution (13F) 4,193,497 3.76% 2026-09-30

Share count 111,610,531 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-01
filed 2026-10-26
Ganot Ilan
Option award (A) 150,000 – –
2026-10-19
filed 2026-10-20
Brooks Gabriel
Sale (S) 4,374 $5.62 97,241
2026-10-18
filed 2026-10-20
Brooks Gabriel
Option exercise (M) 9,750 – 101,615
2026-10-18
filed 2026-10-20
Brooks Gabriel
Option exercise (M) 9,750 – –
2026-10-02
filed 2026-10-06
SMITH IAN F
Option exercise (M) 3,440 – 141,585

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full SLDB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLDB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.